Silence Therapeutics (SLN) Total Current Liabilities: 2019-2025
Historic Total Current Liabilities for Silence Therapeutics (SLN) over the last 7 years, with Sep 2025 value amounting to $17.4 million.
- Silence Therapeutics' Total Current Liabilities rose 179.09% to $17.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.4 million, marking a year-over-year increase of 179.09%. This contributed to the annual value of $16.8 million for FY2024, which is 24.69% down from last year.
- Per Silence Therapeutics' latest filing, its Total Current Liabilities stood at $17.4 million for Q3 2025, which was up 17.68% from $14.8 million recorded in Q2 2025.
- Silence Therapeutics' 5-year Total Current Liabilities high stood at $25.7 million for Q4 2022, and its period low was -$30.6 million during Q3 2022.
- Its 3-year average for Total Current Liabilities is -$3.7 million, with a median of -$18.0 million in 2024.
- Its Total Current Liabilities has fluctuated over the past 5 years, first crashed by 80.00% in 2021, then skyrocketed by 207.13% in 2025.
- MRQ analysis of 5 years shows Silence Therapeutics' Total Current Liabilities stood at $20.4 million in 2021, then increased by 25.89% to $25.7 million in 2022, then decreased by 13.22% to $22.3 million in 2023, then fell by 24.69% to $16.8 million in 2024, then rose by 3.31% to $17.4 million in 2025.
- Its Total Current Liabilities stands at $17.4 million for Q3 2025, versus $14.8 million for Q2 2025 and $19.3 million for Q1 2025.